Recovery & Healing

BPC-157 5mg / TB-500 5mg research blend for laboratory studies. Pharmaceutical-grade dual peptide for in-vitro research only. Not for human consumption.

• Thymosin Beta-4 Derivative: 43-amino acid peptide (Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH), derived from naturally occurring thymosin beta-4 (70-80% of beta-thymosins), 2,000+ publications, N-terminal acetylation for enhanced stability
• Multi-Pathway Regeneration: G-actin sequestration (Kd 0.5-0.7 μM), cell migration promotion, VEGF upregulation via Wnt/β-catenin/Lef-1, angiogenesis, PI3K/Akt/eNOS survival pathway, anti-fibrotic via TGF-β1 suppression
• Clinical Status: No FDA-approved human drug, all therapeutic data preclinical (wound healing, cardiac repair, pulmonary fibrosis, Alzheimer's neuroprotection), extensive safety profile in animal models

MOTS-c mitochondrial-derived peptide (40mg). 16-AA sequence MRWQEMGYIFYPRKLR, C₁₀₁H₁₅₂N₂₈O₂₂S₂, ~2,174 Da, CAS 1627580-64-6. AMPK activator via folate-AICAR pathway. ≥98% purity. Lab research only.

• Synthetic mitochondria-targeted tetrapeptide (D-Arg-Dmt-Lys-Phe-NH₂) that selectively concentrates 5,000-fold at inner mitochondrial membrane through high-affinity cardiolipin binding
• FDA-approved September 2025 as Forzinity for Barth syndrome — first FDA-approved mitochondria-targeted therapeutic
• Extensively validated in 200+ peer-reviewed publications spanning cardiac, renal, neurological, and musculoskeletal research; multiple Phase 2/3 clinical trials completed

• Nonapeptide Neuromodulator: 9-amino acid sequence (WAGGDASGE), ≥98% purity
• Sleep Architecture: Delta-wave EEG activity induction without REM suppression or sedation
• Multisystem Research: 200+ publications (1977-2026), validated in double-blind human trials

• Leucine Dipeptide: Two L-leucine residues (Leu-Leu), 244.33 Da, ≥98% purity
• PEPT1 Transport System: Active absorption via proton-coupled peptide transporter in small intestine
• Muscle Protein Synthesis: Enhanced mTORC1 activation and 42% greater anabolic response versus free leucine